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ABSTRACT
Introduction Current treatment regimens for multidrug- 
resistant tuberculosis (MDR- TB) are long, poorly tolerated 
and have poor outcomes. Furthermore, the costs of 
treating MDR- TB are much greater than those for treating 
drug- susceptible TB, both for health service and patient- 
incurred costs. Urgent action is needed to identify short, 
effective, tolerable and cheaper treatments for people with 
both quinolone- susceptible and quinolone- resistant MDR- 
TB. We present the protocol for an economic evaluation 
(PRACTECAL- EE substudy) alongside an ongoing clinical 
trial (TB- PRACTECAL) aiming to assess the costs to 
patients and providers of new regimens, as well as their 
cost- effectiveness and impact on participant poverty 
levels. This substudy is based on data from the three 
countries participating in the main trial.
Methods and analysis Primary cost data will be collected 
from the provider and patient perspectives, following 
economic best practice. We will estimate the probability 
that new MDR- TB regimens containing bedaquiline, 
pretomanid and linezolid are cost- effective from a societal 
perspective as compared with the standard of care for 
MDR- TB patients in Uzbekistan, South Africa and Belarus. 
Analysis uses a Markov model populated with primary cost 
and outcome data collected at each study site. We will also 
estimate the impact of new regimens on prevalence of 
catastrophic patient costs due to TB.
Ethics and dissemination Ethical approval has been 
obtained from the London School of Hygiene & Tropical 
Medicine and Médecins Sans Frontières. Local ethical 
approval will be sought in each study site. The results of 
the economic evaluation will be shared with the country 
health authorities and published in a peer- reviewed 
journal.
Trial registration number  ClinicalTrials. gov Registry 
(NCT04207112); Pre- results.
INTRODUCTION
Multidrug- resistant tuberculosis (MDR- TB), 
defined as TB resistant to at least isoniazid 
and rifampicin, is an urgent public health 
issue. The current treatment regimen for 
MDR- TB has poor outcomes and costs of 
treatment are greater than those for treat-
ment of drug- susceptible TB, both in terms of 
costs to the health service as well as patient- 
incurred costs.1 2 Key changes to recommen-
dations for MDR- TB treatment regimens 
were published recently by the WHO after 
an assessment of new evidence.3 In this rapid 
communication, three main changes to the 
standard MDR regimen were made: first, the 
withdrawal of injectable antibiotics; second, 
the inclusion of bedaquiline in a recom-
mended longer regimen (ie, 20 months) 
and third, the recommendation of use for 
a shorter regimen only for specific condi-
tions. It also highlights the urgent need for 
evidence to inform better optimal treatment 
choices for MDR- TB patients. Economic 
evaluations of such bedaquiline- containing 
regimens will provide additional important 
Strengths and limitations of this study
 ► This study will evaluate the cost- effectiveness and 
poverty impact of new regimens for multidrug- 
resistant tuberculosis (MDR- TB) using prospectively 
collected primary data and modelling methods.
 ► Analyses will inform decision- making at national 
and global levels, while meeting the urgent need for 
evidence on improved drug regimens for MDR- TB.
 ► This will be one of the first cost- effectiveness stud-
ies on 6- month- long all- oral regimens for MDR- TB 
alongside a randomised controlled trial.
 ► The study is taking place in countries with a high 
prevalence of anti- TB drug resistance as well as a 
country with a high rate of HIV coinfection, covering 
some of the most challenging scenarios for MDR- TB 
treatment.
 ► Depending on recruitment progress at each trial site, 
sample sizes for patient costings may be restricted.
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information for decision makers who need to consider 
its economic value along with clinical efficacy when plan-
ning for introduction.
TB- PRACTECAL is a randomised controlled trial to 
evaluate the safety and efficacy of investigational regi-
mens containing bedaquiline and pretomanid for the 
treatment of MDR- TB (see figure 1) ( ClinicalTrials. gov 
study registration NCT02589782). It has been designed 
in two stages; stage 1 is a phase II trial aiming to identify 
two regimens containing bedaquiline and pretomanid for 
further evaluation based on safety and efficacy outcomes 
after 8 weeks of treatment. Stage 2 is a phase III trial to 
evaluate the safety and efficacy of the two investigational 
regimens containing bedaquiline and pretomanid, 
selected in stage 1, compared with the standard of care 
(SoC) at 72 weeks post randomisation. We present the 
protocol for an economic evaluation (PRACTECAL- EE 
substudy), taking place alongside the TB- PRACTECAL 
trial. This substudy aims to assess the costs to patients 
and providers of such regimens, and to estimate the cost- 
effectiveness and impact on poverty levels for participants 
of introduction of new MDR- TB regimens in the three 
countries participating in the main trial.
Our decision problem is stated as the economic evalu-
ation of the new treatment regimen for both quinolone- 
susceptible and quinolone- resistant MDR- TB patients, 
in order to inform evidence synthesis to Grading of 
Recommendations Assessment, Development, and Eval-
uation (GRADE) standards at a global level, and health 
technology assessments (HTA) in the trial host countries, 
as applied to regimens for MDR- TB. For both national 
and global assessments, the review of economic evidence 
produced alongside clinical trials focuses around patient 
outcomes and then on resources needed to answer the 
question of whether a new regimen should be considered 
for introduction. Population level and equity consid-
erations can also be included, especially during the 
second stage, where the decision problem has advanced 
from whether to recommend a new regimen to how to 
introduce it to achieve maximum health outcomes with 
limited budgets.
OBJECTIVES
The overall aim of this substudy is to estimate the proba-
bility that 6- month all- oral MDR- TB regimens containing 
bedaquiline and pretomanid will be cost- effective from 
a societal perspective as compared with the SoC for 
MDR- TB patients in three settings: Uzbekistan, South 
Africa and Belarus.
A secondary aim is to assess the costs from a provider 
perspective of treating patients with these new regimens 
and estimate the impact of new regimens on prevalence 
of catastrophic costs due to TB.
The specific objectives of this substudy are, in each 
setting:
1. To assess the costs from a provider’s perspective for se-
lected facilities in the intervention and control arms.
2. To assess the costs from a patient’s perspective for a 
sample of patients seeking care in study facilities in the 
intervention and control arms.
3. To estimate the prevalence of catastrophic costs in the 
intervention and control arms.
4. To assess the probability of new regimens being cost- 
effective at different willingness- to- pay thresholds from 
a societal perspective using a Markov model.
METHODS AND ANALYSIS
Study design
This substudy is a cost- effectiveness analysis alongside a 
clinical trial. We will evaluate the total costs and effects of 
the study regimen (intervention) against the locally used 
WHO- approved regimens for treatment of multidrug- 
resistant or extensively drug- resistant TB (M/XDR- TB) 
(control) using a Markov model populated with primary 
cost and outcome data collected at each study site.
This substudy will take place in three settings: Uzbeki-
stan, South Africa and Belarus. The selection of countries 
and facilities in each country is based on their participa-
tion in the TB- PRACTECAL trial. In Uzbekistan, the trial 
is taking place in Tashkent city and six rayons (districts) 
in Karakalpakstan, in Western Uzbekistan (Nukus city, 
Takhiatash, Chimbay, Kegeily and Xodjeli rayons) 
implemented by the Republican Specialised Scientific- 
Practical Medical Centre for Phthisiology and Pulmon-
ology of the Republic of Uzbekistan. In South Africa, 
the trial is being conducted in Doris Goodwin and Don 
McKenzie Hospitals through the Tuberculosis and HIV 
Investigative Network, and Helen Joseph and King Dinu-
Zulu Hospitals though the Clinical HIV Research Unit at 
the University of the Witwatersrand. In Belarus, the trial 
is taking place in Minsk city and Oblast, implemented by 
the Republican Scientific and Practical Centre for Pulm-
onology and Tuberculosis of the Republic of Belarus. 
The trial sites were selected based on their likely ability 
Figure 1 TB- PRACTECAL intervention and control drug 
regimens. B, bedaquiline (400mg daily for 2 weeks then 
200mg three times per week for 22 weeks); Cfz, Clofazimine 
(50mg (less than 33 kg), 100 mg (more than 33 kg) for 24 
weeks); Mfx, moxifloxacin(400 mg once daily for 24 weeks); 
Pa, pretomanid (200mg daily for 24 weeks); Lzd, linezolid 
(600mg for 16 weeks and then reduced to 300mg per day), 
SoC, Standard of care regimen locally approved and as much 
as possible conforming to the WHO recommendations for 
treatment of M/XDR- TB.
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to recruit at least 50 patients into the trial, together 
with the capacity to safely manage complex M/XDR- TB 
patients.
Our population of interest will be adults with Myco-
bacterium tuberculosis resistant to at least isoniazid and 
rifampicin by either molecular or phenotypic drug 
susceptibility testing. The sample size for the overall trial 
is 630. Patient enrolment in TB- PRACTECAL is currently 
underway, and cost data collection is anticipated to start 
in October 2020. The distribution of patient recruit-
ment by country in the TB- PRACTECAL trial is expected 
to be approximately 280 patients in South Africa, 100 
patients in Belarus and 250 patients in Uzbekistan. For 
cost data collection from the patient perspective, the 
numbers recruited into PRACTECAL- EE will be propor-
tional to the overall trial, depending on the starting dates 
and numbers consenting. The level of patient costs and 
the expected change as a result of the intervention is 
unknown, therefore we have not done a sample size calcu-
lation for the patient costing survey. However, a sample 
size between 100 and 350 is comparable to previous 
patient costing studies from South Africa, Bangladesh, 
Indonesia, Tanzania and Brazil, which were found to give 
reasonable estimates with acceptable uncertainty.4–8 Data 
collection for costings from the provider perspective will 
be done at all trial sites in each country. Cost data collec-
tion is expected to be completed before the end of the 
main trial in 2021.
The perspective of the cost- effectiveness analysis 
will be societal, following requirements for the WHO 
guideline development process and best practice.9 10 
The societal perspective will include all costs associated 
with delivery of care, regardless of whether incurred 
by providers or by patients and their households. The 
cost- effectiveness analysis will not include any costs or 
savings associated with informal support networks in 
the community, other caregivers or production costs at 
a societal level.
We will analyse and present costs incurred by the 
health system separately to inform future health system 
budgeting and allocation. We will also estimate the preva-
lence of catastrophic costs due to TB encountered at the 
household level in each trial arm. This analysis will help 
to inform whether the intervention facilitates progress 
towards the end TB target of ‘zero catastrophic costs due 
to TB by 2020’.11
The model- based economic evaluation will focus on 
the comparison of two regimens selected for complete 
follow- up with SoC. The local SoC MDR- TB regimen will 
be used as the main comparator in the cost- effectiveness 
analysis. This corresponds to the control arm in the 
TB- PRACTECAL trial. This SoC arm will simulate the 
cohort following the most recent recommended regimen 
in each country.
The time frame for the cost- effectiveness analysis will be 
the time between the start of treatment and death of the 
entire simulated cohort in the Markov model.
Data collection
Data will be collected from various sources (trial, liter-
ature, national databases, questionnaires). Four types 
of data will need to be collected: (1) outcome data; (2) 
event and service use data; (3) cost data related to TB and 
(4) cost data unrelated to TB.
Outcome data
Event data from the trial for both intervention and 
control arms (for each patient type, age category, sex) 
will be collected on: number, reason (including but not 
limited to serious adverse events) and length of stay in 
hospital in each 24- week period over 108 weeks; mean 
number of outpatient visits per month in each 24- week 
period by reason over 108 weeks; mean number of moni-
toring tests in each 24- week period by reason over 108 
weeks; duration and outcomes for serious adverse events, 
focusing on QT prolongation, indication of hepatotox-
icity, hearing loss or nephrotoxicity and any service used 
to diagnose and treat adverse events as above. We will 
review the published literature (including data reported 
to WHO) on probabilities of relapse and life expectancy 
in each setting to calculate disability- adjusted life years 
(DALYs) averted by the intervention.
Cost data
Provider perspective
Primary data collection from the provider perspective 
will gather information on the resources used to provide 
TB care under the new regimens as compared with the 
SoC. We will collect the economic, real- world, full costs 
of provision of MDR- TB care in intervention and control 
arms, from each setting alongside the TB- PRACTECAL 
trial following best- practice costing methods.12 We will 
employ standardised tools and instruments developed in 
the VALUE- TB study and in line with the Global Health 
Cost Consortium Reference Case for Estimating the 
Costs of Global Health Services and Interventions.12 Data 
collection will involve interviews with healthcare workers, 
retrospective review of project and expenditure records, 
physical measurement of building space and observation 
of service delivery. An ingredients approach will be taken, 
where the value of inputs is based on quantities and unit 
prices, including staff salaries, building space, training, 
supplies, drugs, equipment and overheads.
Costs related to adverse events will be estimated from 
the literature; if not available, we will then estimate the 
costs using an ingredient approach based on treatment 
protocols. We will aim to exclude costs related to trial 
only activities; however, data collection at trial sites may 
produce biased observations in terms of non- standard 
service delivery. We will aim to account for this in the 
uncertainty analysis of the cost effectiveness results. For 
this analysis, it may be necessary to interview national 
programme- level staff or access national salary scales and 
other information to understand the likely cost if new 
regimens were to be provided through the public sector 
and scaled up to the national level.
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Patient perspective
From a patient’s perspective, we will collect self- reported 
data on patient- incurred costs related to accessing care 
in the intervention and control arms through a survey of 
patients enrolled in the TB- PRACTECAL trial (patient 
costing questionnaires are available for download at: 
https:// doi. org/ 10. 17037/ DATA. 00001799). Costs 
related to accessing the standard TB services will then be 
estimated from the information collected in the control 
arm. Information on costs encountered by TB patients 
and their households will be collected. Patient and house-
hold costs will include direct and indirect costs incurred 
because of their TB diagnosis. Direct costs will be defined 
as out- of- pocket medical (including consultation fees and 
any out- of- pocket payment for medicines and diagnos-
tics) and non- medical expenses (including travel costs of 
participants and guardians, food costs incurred while in 
hospital, money spent buying any special foods or dietary 
supplements due to illness and any interest incurred 
on loans taken out to meet the costs of out- of- pocket 
payments). Cost will be estimated for the participant’s 
local clinic (our study clinic), other public facilities, 
general practitioners, hospitals, traditional healers and 
pharmacies. Indirect costs will be estimated as the oppor-
tunity cost of time spent seeking care, plus any lost 
productivity due to illness.
Questionnaires will include detailed questions on 
care seeking behaviour and the above- mentioned cost 
variables. Questionnaires will also capture information 
about strategies adopted by participants to cope with 
costs of illness, including: taking interest- bearing loans 
from lenders, borrowing money from friends or rela-
tives, selling personal goods and receipt of grants or 
charitable donations. Patient costs will be estimated for 
the entire episode of TB illness, from symptom onset to 
completion of treatment. Patient/household cost data 
will be collected retrospectively during visits aligned with 
other substudies, at baseline and weeks 24 and 48 for 
all patients. For those patients already enrolled that are 
answering their first patient cost questionnaire in week 
24, we will also administer sections 1 and 2 of the base-
line questionnaire, and costs prior to week 12 will be esti-
mated based on the average cost per visit.
Collection of patient cost data within an economic eval-
uation of a clinical trial can be challenging and requires 
careful trade- off between available methodological 
approaches.13 As cost data collection for this substudy 
will be nested within the main trial, our approach to 
collecting cost data aims to limit survey fatigue wherever 
possible; for example, we use a recall- based survey rather 
than a cost diary. This is in line with existing methods 
for trial- based economic evaluation, but may result in 
underestimation of household costs due to potential 
telescoping and recall biases. Demographic data will be 
obtained from the main trial datasets, including gender, 
age, ethnicity and nationality and the impact of illness on 
normal productive patterns.
Analysis
Cost analysis
A descriptive analysis will be included in the patient 
cost analysis. We will use χ2 tests to determine the level 
to which the substudy sample is a representative of the 
sample in the main study for selected demographics.
Provider costs related to TB care will be estimated as 
one- time costs required for introduction and recurrent 
costs required for sustaining the intervention. Costs will 
be analysed as total costs, unit costs and incremental 
costs disaggregated by input categories (ie, staff, capital, 
drugs). Any costs measured from a provider or patient 
perspective necessary only for research purposes (such 
as nurse or patient time allocated to administration of 
patient consent) will be excluded from the analysis.
Patient costs will be analysed in total and by subcategory, 
including direct medical costs (drugs, diagnostics, etc), 
direct non- medical costs. (eg, transport, special food or 
supplements), productivity loss associated with ill health 
(inability to work or reduced productivity while at work) 
and/or time costs associated with seeking care (eg, travel 
and consultation time for health facility visits). Patient 
costs data will be included as part of societal costs for the 
cost- effectiveness analysis. In addition, a separate anal-
ysis will be conducted to estimate the prevalence of cata-
strophic costs in intervention and control populations.
The main trial is expected to report on its main outcomes 
in 2021; all cost information collected in the previous year 
will be inflated to 2021 currency and converted from local 
currency units to US dollars and purchasing- power parity 
using exchange rates for that year.
Cost-effectiveness analysis
Based on the requirements of the GRADE process 
for global- level evaluations, we will develop a Markov 
model to follow a cohort of MDR- TB patients under the 
different treatment options. A Markov model is appro-
priate for estimating the expected effects of the interven-
tion at patient level, including: (1) improved treatment 
efficacy (better cure rate); (2) improved safety profile 
(fewer adverse events) and (3) shorter regimen (higher 
completion rate). The treatment effects on transmission 
of MDR- TB will not be modelled.
We will estimate incremental costs, cost per death 
averted and cost per DALY averted of the intervention(s) 
to the comparator. Discount rates of 3% will be used to 
discount both costs and effects in the primary analysis, 
following international reference case recommenda-
tions.9 12 We will vary these rates in sensitivity analyses. We 
will explore the effects of sampling uncertainty for the 
estimated incremental cost and incremental effectiveness 
parameters, together with the impact of methodological 
assumptions (such as discount rate, study perspective) 
using deterministic and probabilistic sensitivity analyses. 
Where applicable, we will report differences in costs, 
outcomes or cost- effectiveness that can be explained by 
variations between subgroups of patients with different 
baseline characteristics. Results will be presented using 
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cost- effectiveness acceptability curves for a range of will-
ingness to pay thresholds.
The main outputs from the model will include:
 ► Incremental cost incurred per DALY averted with the 
intervention regimen, compared with the SoC from a 
societal perspective.
 ► Incremental cost per DALY averted with the interven-
tion regimen, compared with the SoC from a provider 
perspective.
Secondary outcome measures from the model will 
include:
 ► The mean cost per month of treatment for different 
regimens and type of patient (MDR- TB, pre- XDR- TB 
(resistant to fluoroquinolone) and XDR- TB).
 ► The mean cost per course of treatment for different 
types of patients (MDR- TB, pre- XDR- TB (resistant 
to fluoroquinolone), XDR- TB) and by category 
(training, monitoring, service delivery and drugs).
 ► The incremental total cost of intervention for the trial 
population, over the trial duration.
 ► The incremental total cost of intervention for the 
modelling cohort, over a lifetime horizon.
The model will be parameterised using primary data 
from the TB- PRACTECAL trial on effectiveness (outcomes 
post 108 weeks of trial follow- up) and costs, combined 
with secondary data on national population characteris-
tics and outcomes with the current SoC. Expert opinion 
will be used where no data are available, for example, esti-
mating the extent to which patients return to care after 
default. All model parameters will be reviewed by a panel 
of local experts.
We will perform additional analyses disaggregated by 
patient type, sex, age and socioeconomic status, and the 
main determinants of cost- effectiveness, using a sensitivity 
analysis to inform decisions for other settings. We will also 
conduct a sensitivity analysis with intermediate durations, 
as cost estimates based on study subjects’ lifetimes can be 
marked by very large confidence intervals.
ETHICS AND DISSEMINATION
Ethical approval has been obtained from the London 
School of Hygiene & Tropical Medicine (reference 
17580) and Médecins Sans Frontières (reference 1541c). 
Local ethical approval is currently being sought from 
relevant agencies in each study setting. In South Africa, 
this includes PharmaEthics and University of the Witwa-
tersrand Human Research’s ethics committee. In Uzbeki-
stan, this is the ethical committee under Ministry of Health 
of the Republic of Uzbekistan. In Belarus, this is the ethics 
committee of the State Institution Republican Scientific 
and Practical Centre of Pulmonology and Tuberculosis, 
and the Centre of Expertise for Testing in Healthcare. 
For the provider costings, staff will be informed of the 
study in their language of preference and will be asked 
to give written informed consent before participating 
in the study. Approval from the hospital management 
at each site will be sought and obtained before starting 
the provider cost data collection. We will seek written 
informed consent of patients before conducting the 
patient costing questionnaire.
Following the end of the research project and publica-
tion of findings, cost data will be made available through 
an approved and curated open- access platform. All data 
will be fully anonymised before being placed in the public 
domain.
The results of the economic evaluation will be published 
in a peer- reviewed journal. If the TB- PRACTECAL trial 
successfully identifies effective and safe regimens, the 
results of this study will inform a GRADE process by 
potentially answering a specific population, intervention, 
comparison, and outcomes (PICO) question on cost- 
effectiveness of the PRACTECAL regimens, as applied 
by the WHO guidelines committee processes. The results 
may also be used for HTA in the trial host countries.
Patient and public involvement
Patients and, where feasible, the community have been 
engaged in the set- up and implementation stages of the 
main TB- PRACTECAL trial.14 15 Prior to rollout of the 
PRACTECAL- EE questionnaires, we will conduct consul-
tations with patients and/or health workers in each setting 
to gain a sense of the types of costs encountered by TB 
patients and how best to approach patients to engage in 
a conversation about resources before rolling out costing 
data collection.
DISCUSSION
The novel regimens in the TB- PRACTECAL trial could 
potentially improve the patient experience by shortening 
treatment duration, reducing pill burden and reducing 
adverse events. If the study regimens are proven non- 
inferior to the standard of care, evidence on the cost- 
effectiveness of these regimens will be critical to help 
policy makers evaluate the economic impact of adopting 
these new regimens. The PRACTECAL- EE substudy will 
provide evidence from both the patients’ and health 
systems’ perspective to assist in policy development 
following publication of outcomes from the clinical trial.
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